Literature DB >> 16116233

Gene expression profiling reveals multiple protective influences of the peptide alpha-melanocyte-stimulating hormone in experimental heart transplantation.

Gualtiero Colombo1, Stefano Gatti, Flavia Turcatti, Andrea Sordi, Luigi R Fassati, Ferruccio Bonino, James M Lipton, Anna Catania.   

Abstract

Novel therapies are sought to increase efficiency and survival of transplanted organs. Previous research on experimental heart transplantation showed that treatment with the anti-inflammatory peptide alpha-melanocyte-stimulating hormone (alpha-MSH) prolongs allograft survival. The aim of the present research was to determine the molecular mechanism of this protective activity. Gene expression profile was examined in heart grafts removed on postoperative days 1 and 4 from rats treated with saline or the synthetic alpha-MSH analog Nle4DPhe7 (NDP)-alpha-MSH. On postoperative day 1, the peptide induced expression of cytoskeleton proteins, intracellular kinases, transcription regulators, metallopeptidases, and protease inhibitors. Conversely, NDP-alpha-MSH repressed immune, inflammatory, cell cycle, and protein turnover mediators. Later effects of alpha-MSH treatment included down-regulation of oxidative stress response and up-regulation of ion channels, calcium regulation proteins, phosphatidylinositol signaling system, and glycolipidic metabolism. NDP-alpha-MSH exerted its effects on both Ag-dependent and -independent injury. The results indicate that NDP-alpha-MSH preserves heart function through a broad effect on multiple pathways and suggest that the peptide could improve the outcome of organ transplantation in combination with immunosuppressive treatments.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16116233     DOI: 10.4049/jimmunol.175.5.3391

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Selective melanocortin MC4 receptor agonists reverse haemorrhagic shock and prevent multiple organ damage.

Authors:  D Giuliani; C Mioni; C Bazzani; D Zaffe; A R Botticelli; S Capolongo; A Sabba; M Galantucci; A Iannone; P Grieco; E Novellino; G Colombo; A Tomasi; A Catania; S Guarini
Journal:  Br J Pharmacol       Date:  2007-01-22       Impact factor: 8.739

2.  Local treatment with alpha-melanocyte stimulating hormone reduces corneal allorejection.

Authors:  Pedram Hamrah; Zdenka Haskova; Andrew W Taylor; Qiang Zhang; Bruce R Ksander; M Reza Dana
Journal:  Transplantation       Date:  2009-07-27       Impact factor: 4.939

3.  Alpha-melanocyte-stimulating hormone during exercise recovery has prognostic value for coronary artery disease.

Authors:  Dejana Vidojevic; Stefan Seman; Ratko Lasica; Milorad Tesic; Marija Saric Matutinovic; Snezana Jovicic; Svetlana Ignjatovic; Ross Arena; Svetozar Damjanovic; Dejana Popovic
Journal:  Hormones (Athens)       Date:  2021-02-01       Impact factor: 2.885

Review 4.  Activation of Melanocortin Receptors as a Potential Strategy to Reduce Local and Systemic Reactions Induced by Respiratory Viruses.

Authors:  Caterina Lonati; Stefano Gatti; Anna Catania
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-10       Impact factor: 5.555

5.  Inflamed phenotype of the mesenteric microcirculation of melanocortin type 3 receptor-null mice after ischemia-reperfusion.

Authors:  Giovanna Leoni; Hetal B Patel; André L F Sampaio; Felicity N E Gavins; Joanne F Murray; Paolo Grieco; Stephen J Getting; Mauro Perretti
Journal:  FASEB J       Date:  2008-08-29       Impact factor: 5.191

6.  α-MSH analogue attenuates blood pressure elevation in DOCA-salt hypertensive mice.

Authors:  Petteri Rinne; Anna-Maija Penttinen; Wendy Nordlund; Markku Ahotupa; Eriika Savontaus
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.